News

The new contract is expected to increase both production and reduce production costs targeting increased sales volume and market share. Imatinib’s market in Russia for 2012 amounted to

Used by Genzyme for its internal product development and external sublicensing, the technology allows a gene therapy Adeno-Associated Viral vector (AAV) to package and deliver more potent therapeutic

Commenting on the investment, Penn Pharma chief executive officer Richard Yarwood said the move was fuelled by its demonstrated ability to provide pragmatic and timely solutions for their

Prolia is approved in the US to treat postmenopausal women with osteoporosis at high risk for fracture and to increase bone mass in men with osteoporosis at high

The approval, which is applicable to all 28 EU member states, has triggered $6m milestone payment to Curis from Genentech, a member of the Roche Group. Curis is

Commenting on the development Cipla managing director and global CEO Subhanu Saxena was quoted by The Economic Times as saying that the investment is aligned with the company’s

The research agreement involves the evaluation of partially refined mixtures as well as individual compounds. The aquatic environment is a source which consists of metabolically active organisms and

Under the terms of the long-term research agreement, Sobi will receive exclusive rights to commercialize XIAPEX in 28 European countries, including Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth

The research agreement involves the evaluation of partially refined mixtures as well as individual compounds. The aquatic environment is a source which consists of metabolically active organisms and